Epilepsy Cell Models for Research

Epilepsy is one of the most common neurological disorders, affecting over 50 million people worldwide (WHO, 2023). The global incidence is approximately 2.4 million new cases per year. The prevalence is higher in low- and middle-income countries, where 80% of people with epilepsy reside. The disease has a significant impact on quality of life, with increased morbidity and mortality. The 5-year survival rate for epilepsy is generally good, but patients with drug-resistant epilepsy have a higher risk of premature death. Key risk factors include genetic predisposition, head trauma, stroke, infections, and developmental disorders. The economic burden is substantial, with costs related to treatment, lost productivity, and caregiving.

Epilepsy is a heterogeneous disease with many subtypes, making it an ideal model for studying neuronal excitability, synaptic transmission, and network dynamics. The availability of well-characterized genetic mutations (e.g., in ion channels, neurotransmitter receptors) allows for mechanistic studies. Public datasets, such as those from the Human Brain Atlas and the Epilepsy Genetics Initiative, provide valuable resources. Open questions include the mechanisms of epileptogenesis, drug resistance, and the role of neuroinflammation. Gene-edited cell models are essential for dissecting these pathways and developing targeted therapies.

Epilepsy arises from an imbalance between excitation and inhibition in the brain. Key pathways include:

• • Ion channel dysfunction: Mutations in voltage-gated sodium channels (e.g., SCN1A, SCN2A), potassium channels (KCNQ2, KCNQ3), and calcium channels (CACNA1A) alter neuronal excitability.
• • Synaptic transmission defects: Mutations in GABA receptors (GABRG2, GABRA1) and glutamate receptors (GRIN2A) disrupt inhibitory or excitatory signaling.
• • mTOR pathway dysregulation: Mutations in TSC1/TSC2 lead to hyperactivation of mTOR, causing abnormal neuronal development and network hyperexcitability.
• • Neuroinflammation: Activation of microglia and astrocytes, release of pro-inflammatory cytokines, and blood-brain barrier dysfunction contribute to seizure generation.

Data from ClinVar, NCBI Gene, and COSMIC.

Epilepsy involves complex signaling networks:

• • mTOR signaling: Key nodes include PI3K, AKT, TSC1/2, mTORC1, and S6K. Dysregulation leads to abnormal neuronal growth and synaptic plasticity.
• • MAPK/ERK pathway: Involved in synaptic plasticity and neuronal survival. Mutations in genes like BRAF and KRAS can cause epilepsy.
• • Wnt/β-catenin pathway: Regulates neuronal development and synaptic function. Aberrant activation is linked to epileptogenesis.
• • Neurotrophin signaling: BDNF/TrkB pathway modulates synaptic strength and neuronal excitability.

Organoids, such as cerebral organoids derived from iPSCs, recapitulate 3D brain architecture and are useful for studying network activity and drug responses.

Animal models are essential for studying epilepsy in vivo:

• • Genetic models: Knock-in mice carrying human mutations (e.g., SCN1A, KCNQ2) recapitulate disease phenotypes.
• • Chemoconvulsant models: Administration of kainic acid or pilocarpine induces status epilepticus and chronic epilepsy.
• • Kindling model: Repeated electrical stimulation leads to progressive seizure susceptibility.
• • PDX models: Patient-derived xenografts are less common for epilepsy but used for brain tumors associated with seizures.

CRISPR-based gene editing enables the creation of isogenic cell lines with precise mutations. For example, a SCN1A knockout SH-SY5Y line can be generated to study loss-of-function effects on neuronal excitability. Similarly, a KCNQ2 knock-in line with a pathogenic variant can model gain-of-function or dominant-negative effects. These models are commercially available and sequence-verified, accelerating research without the need for time-consuming editing. They are essential for drug screening, target validation, and mechanistic studies.

Gene-edited cell lines are used to validate the role of specific genes in epilepsy. For example, knocking out SCN1A in neurons reduces sodium current and increases seizure-like activity, confirming its role in Dravet syndrome. Knock-in lines with patient-specific mutations allow for studying genotype-phenotype correlations.

Isogenic pairs (wild-type vs. mutant) are used in high-throughput screens to identify compounds that selectively affect mutant cells. For example, a KCNQ2 mutant line can be used to screen for potassium channel openers. Resistance mechanisms can be studied by exposing cells to antiepileptic drugs and selecting for resistant clones.

CRISPR screens can identify synthetic lethal interactions, where mutations in two genes are lethal but each alone is not. This approach can reveal novel drug targets. For example, a screen in SCN1A knockout cells may identify genes that, when silenced, reduce neuronal hyperexcitability, providing potential therapeutic targets.